Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine.

[1]  Y. Shoenfeld,et al.  Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. , 2013, Journal of autoimmunity.

[2]  N. Petrovsky,et al.  A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. , 2013, Vaccine.

[3]  N. Petrovsky,et al.  Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. , 2012, Vaccine.

[4]  A. Musacchio,et al.  Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults , 2011, Human vaccines.

[5]  A. Didierlaurent,et al.  Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach , 2011, BioDrugs.

[6]  Marc Lipsitch,et al.  Vaccine production, distribution, access, and uptake , 2011, The Lancet.

[7]  E. Montomoli,et al.  Current adjuvants and new perspectives in vaccine formulation , 2011, Expert review of vaccines.

[8]  N. Garçon,et al.  The safety evaluation of adjuvants during vaccine development: the AS04 experience. , 2011, Vaccine.

[9]  M. Tao,et al.  Hydrogel-Delivered GM-CSF Overcomes Nonresponsiveness to Hepatitis B Vaccine through the Recruitment and Activation of Dendritic Cells , 2010, The Journal of Immunology.

[10]  O. Leo,et al.  Innate immunity and vaccine adjuvants: From concepts to the development of a unique adjuvant system as04 used for the formulation of a human papillomavirus (hpv) vaccine , 2010 .

[11]  Arnaud M. Didierlaurent,et al.  AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity1 , 2009, The Journal of Immunology.

[12]  Thomas Breuer,et al.  Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. , 2008, Vaccine.

[13]  T. Mitchell,et al.  Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant , 2008, Cellular and Molecular Life Sciences.

[14]  Rino Rappuoli,et al.  Bridging the knowledge gaps in vaccine design , 2007, Nature Biotechnology.

[15]  B. Guy,et al.  The perfect mix: recent progress in adjuvant research , 2007, Nature Reviews Microbiology.

[16]  Brigitte Colau,et al.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.

[17]  J. Brewer.  (How) do aluminium adjuvants work? , 2006, Immunology letters.

[18]  G. Dougan,et al.  Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. , 2005, Vaccine.

[19]  Jeffrey B Ulmer,et al.  Targeting the innate immune response with improved vaccine adjuvants , 2005, Nature Medicine.

[20]  J. Paul Robinson,et al.  Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. , 2005, Vaccine.

[21]  A. Iwasaki,et al.  Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.

[22]  N. Petrovsky,et al.  Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.

[23]  D. Persing,et al.  Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents , 2004, Expert opinion on biological therapy.

[24]  J. Eldridge,et al.  Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A. , 2004, Vaccine.

[25]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[26]  S. Michalek,et al.  Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A , 2003, Infection and Immunity.

[27]  D. Persing,et al.  Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529 , 2003, Expert review of vaccines.

[28]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[29]  H. HogenEsch,et al.  Mechanisms of stimulation of the immune response by aluminum adjuvants. , 2002, Vaccine.

[30]  P. van Damme,et al.  Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. , 2000, Vaccine.

[31]  S. Romagnani.  Th1/Th2 cells. , 1999, Inflammatory bowel diseases.

[32]  A. Krieg,et al.  CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. , 1998, Journal of immunology.

[33]  M. Tomai,et al.  T cell and interferon-gamma involvement in the adjuvant action of a detoxified endotoxin. , 1989, Journal of biological response modifiers.

[34]  F. André.  Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. , 1989, The American journal of medicine.

[35]  B. Yvonnet,et al.  SEVEN-YEAR STUDY OF HEPATITIS B VACCINE EFFICACY IN INFANTS FROM AN ENDEMIC AREA (SENEGAL) , 1986, The Lancet.

[36]  S. Hadler,et al.  Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. , 1986, The New England journal of medicine.

[37]  G. Keating,et al.  Recombinant Hepatitis B Vaccine (Engerix-B®) , 2012, Drugs.

[38]  R. Gupta,et al.  The role of adjuvants and delivery systems in modulation of immune response to vaccines. , 1996, Advances in experimental medicine and biology.